14-6-3-1　ⓔ文献

  1. Kotzen ES, Roy S, et al: Antiphospholipid syndrome nephropathy and other thrombotic microangiopathies among patients with systemic lupus erythematosus. Adv Chronic Kidney Dis, 2019; 26: 376–386.

  2. Mohan C, Putterman C: Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nature reviews Nephrology, 2015.

  3. 土屋尚之：全身性エリテマトーデスの疾患感受性遺伝子．腎と透析，2013; 74: 15–20.

  4. 難病情報センター：令和元年度末現在　特定医療費 (指定難病) 受給者証所持者数．http://www.nanbyou.or.jp/entry/5354.

  5. Jakes RW, Bae SC, et al: Systematic review of the epidemiology of systemic lupus erythematosus in the Asia–Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken), 2012; 64: 159–168.

  6. Hiromura K, Ikeuchi H, et al: A nationwide analysis of outcomes of adult lupus nephritis in Japan. J Am Soc Nephrol, 2018; 29 (Abstract Supplement): 709.

  7. Weening JJ, D’Agati VD, et al: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol, 2004; 15: 241–250.

  8. Bajema IM, Wilhelmus S, et al: Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int, 2018; 93: 789–796.

  9. 池内秀和，廣村桂樹：難治性ループス腎炎のマネジメント．リウマチ科，2018; 60: 315–321.

  10. Hiromura K, Nangaku M: Immune complexes in systemic lupus erythematosus. Systemic Lupus Erythematosus, 2nd ed: Basic, Applied and Clinical Aspects (Tsokos G, ed), Elsevier, 2020; 249–257.

  11. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1997; 40: 1725.

  12. 難病情報センター：全身性エリテマトーデス (SLE) (指定難病49)．https://www.nanbyou.or.jp/entry/215.

  13. Petri M, Orbai AM, et al: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum, 2012; 64: 2677–2686.

  14. Amezcua–Guerra LM, Higuera–Ortiz V, et al: Performance of the 2012 SLICC and the 1997 ACR classification criteria for systemic lupus erythematosus in a real–life scenario. Arthritis Care Res (Hoboken), 2015; 67: 437–441.

  15. Oku K, Atsumi T, et al: Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). Mod Rheumatol, 2018; 28: 642–648.

  16. Aringer M, Costenbader K, et al: 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis, 2019; 78: 1151–1159.

  17. Pollak VE, Pirani CL, et al: The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med, 1964; 63: 537–550.

  18. 大藤　真，宮脇昌二：SLEの疫学―日本におけるSLEの実態．リウマチ，1975; 15: 310–325.

  19. 厚生労働科学研究費補助金難治性疾患等政策研究事業自己免疫疾患に関する調査研究班，日本リウマチ学会編：全身性エリテマトーデス診療ガイドライン2019，南山堂，2019．

  20. Bao H, Liu ZH, et al: Successful treatment of Class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol, 2008; 19: 2001–2010.

  21. Liu Z, Zhang H, et al: Multitarget therapy for Induction treatment of lupus nephritis: a randomized, controlled trial. Ann Intern Med, 2015; 162: 18–26.

  22. Rovin BH, Solomons N, et al: A randomized, controlled double–blind study comparing the efficacy and safety of dose–ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int, 2019; 95: 219–231.

  23. Andreoli L, Bertsias GK, et al: EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis, 2017; 76: 476–485.